Q3 2023 EPS Estimates for Hepion Pharmaceuticals, Inc. Decreased by Brookline Capital Management (NASDAQ:HEPA)

Posted by on Oct 7th, 2023

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA – Free Report) – Investment analysts at Brookline Capital Management decreased their Q3 2023 EPS estimates for Hepion Pharmaceuticals in a report issued on Tuesday, October 3rd. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($2.68) per share for the quarter, down from their prior forecast of ($2.65). The consensus estimate for Hepion Pharmaceuticals’ current full-year earnings is ($8.99) per share. Brookline Capital Management also issued estimates for Hepion Pharmaceuticals’ Q4 2023 earnings at ($2.60) EPS and FY2024 earnings at ($11.31) EPS.

Hepion Pharmaceuticals Trading Up 1.8 %

NASDAQ HEPA opened at $4.60 on Friday. Hepion Pharmaceuticals has a 1 year low of $4.51 and a 1 year high of $23.85. The firm has a market capitalization of $17.66 million, a price-to-earnings ratio of -0.39 and a beta of 1.75. The firm’s 50 day simple moving average is $6.43 and its 200 day simple moving average is $10.01.

Hedge Funds Weigh In On Hepion Pharmaceuticals

A number of institutional investors have recently modified their holdings of HEPA. Envestnet Asset Management Inc. lifted its stake in Hepion Pharmaceuticals by 131.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 202,978 shares of the company’s stock valued at $61,000 after purchasing an additional 115,437 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Hepion Pharmaceuticals by 85.3% in the 2nd quarter. Renaissance Technologies LLC now owns 234,600 shares of the company’s stock valued at $134,000 after acquiring an additional 108,000 shares during the last quarter. Virtu Financial LLC boosted its holdings in shares of Hepion Pharmaceuticals by 152.8% during the 1st quarter. Virtu Financial LLC now owns 53,501 shares of the company’s stock valued at $42,000 after acquiring an additional 32,336 shares in the last quarter. State Street Corp grew its position in Hepion Pharmaceuticals by 8.1% during the 1st quarter. State Street Corp now owns 348,910 shares of the company’s stock worth $450,000 after acquiring an additional 26,194 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in Hepion Pharmaceuticals by 0.3% in the 1st quarter. BlackRock Inc. now owns 1,602,772 shares of the company’s stock worth $1,245,000 after purchasing an additional 5,206 shares in the last quarter. Institutional investors and hedge funds own 13.50% of the company’s stock.

About Hepion Pharmaceuticals

(Get Free Report)

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.

Featured Stories

Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.